Emerging clinical applications of selected biomarkers in melanoma

Abstract

Michael T Tetzlaff,1 Carlos A Torres-Cabala,1,2 Penvadee Pattanaprichakul,1,3 Ronald P Rapini,2 Victor G Prieto,1,2 Jonathan L Curry1,21Department of Pathology, Section of Dermatopathology, 2Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, ThailandAbstract: Melanoma is a lethal skin disease with a mostly predictable clinical course according to a known constellation of clinical and pathologic features. The distinction of melanoma from benign melanocytic nevus is typically unequivocol; however, there is a subset of tumors known for its diagnostic challenges, development of late metastases, and difficulties in treatment. Several melanocytic tissue biomarkers are available that can facilitate the histopathologic interpretation of melanoma as well as provide insight into the biologic potential and mutational status of this disease. This review describes the clinical application of some of these established and emerging tissue biomarkers available to assess melanocytic differentiation, vascular invasion, mitotic capacity, and mutation status. The selected tissue biomarkers in this review include MiTF, Sox10, D2-40, PHH3, H3KT (anti-H3K79me3T80ph), anti-BRAFV600E, and anti-BAP-1.Keywords: immunohistochemistry, melanocytic differentiation, histone marks, BRAFV600E